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Emergence of survival strategies is a key step for organisms
during evolution. The capacity to adapt from nutrient-rich to
nutrient-poor environments led to the appearance of protein
complexes regulating anabolic and catabolic pathways. The
evolutionarily conserved kinase mTOR (mechanistic target
of rapamycin) emerged as a crucial and central protein for
regulating many different cellular functions in response to
environmental changes.
The kinase mTOR interacts with different partners
to form two distinct complexes, which differentiate from one
to the other by the presence of the regulatory-associated
protein of mTOR (raptor)1 in the mTORC1 and the rapamycin-
insensitive companion of mTOR (rictor)2 in the mTORC2.
These two mTOR complexes integrate intracellular and
extracellular signals, such as presence of growth factors or
amino acids, energy status, oxygen and stress, which lead
to modulation of mTORC1/2-dependent signaling events.
The mTORC1 regulates key cellular pathways like protein
synthesis (through phosphorylation of S6K and 4E-BP1),
autophagy, lipid synthesis, energy metabolism and lyso-
some formation, whereas mTORC2 controls the organi-
zation of the cytoskeleton, cell survival, apoptosis and
metabolism.3 Acting together in a nutrient-rich environ-
ment, these two mTOR complexes positively regulate cell
anabolism and, at the same time, negatively regulate cell
catabolism.
More than 20 years after the discovery of the mTOR
complexes, novel aspects of mTOR regulation are still
emerging and contribute to the growing complexity of these
metabolic sensors. The activation level of mTORC1 is tightly
controlled by many different protein signaling cascades,
leading to adaptation to environmental changes. Precise
regulation of mTORC1 activity is crucial, since its hyperactiva-
tion has been linked to many human disorders, including
metabolic diseases (type 2 diabetes, insulin resistance),
neurological diseases and cancers.3,4
mTORC1 hyperactivation in cancers has been proposed to
contribute to uncontrolled cell proliferation.5 This led to the
development of mTORC1 targeting inhibitors, such as
rapamycin analogs (rapalogs), aimed at blocking prolifera-
tion of cancer cells. While common anticancer drugs also
inhibit mTORC1,6,7 the mechanisms involved are not fully
understood.
In our recentCell Death Discovery publication (doi:10.1038/
cddiscovery.2016.24), we show that treatment with different
chemotherapeutic drugs triggers proteolytic processing of
the mTORC1-specific scaffolding protein raptor. Anti-cancer
compounds targeting mTORC1, such as rapamycin, curcu-
min, etoposide, cisplatin, staurosporine and FasL, initiated
apoptosis in various lymphoma cell lines and promoted
the detection of a raptor-cleaved fragment of 100 kDa. This
proteolytic event was blunted in the presence of specific
caspase inhibitors, indicating that caspases were involved
in this process. In vitro experiments demonstrated that
active recombinant caspase-6 cleaved a recombinant
raptor protein as well as the endogenous raptor in Jurkat
T-cell lysates. Moreover, raptor cleavage was decreased
in caspase-6 knockout (KO) cells, further indicating the
important role of caspase-6 in raptor processing upon
treatment with various drugs. However, at this point, we
cannot exclude that other apoptotic caspases could
play a redundant role in the cleavage of raptor due to the
incomplete inhibition of raptor proteolytic cleavage in caspase-
6 KO cells.
The caspase-specific cleavable residues of raptor were
investigated by mutagenesis and mass spectrometry.
At least two cleavage sites were identified, one within the
N-terminal region and one in the C-terminal part, both yielding
the predicted 100-kDa cleavage fragment of raptor after
treatment of cancer cells with chemotherapeutic drugs.
Interestingly, raptor cleavage induced a decrease in the
interaction between raptor and the mTOR kinase, suggesting
that raptor processing could affect the signalosome of the
mTORC1 (Figure 1). In addition, we observed a striking
decrease of mTORC1 kinase activity towards S6K and 4E-
BP1, which correlated with the processing of raptor upon cell
death induction. Furthermore, use of the raptor cleavage-
resistant mutant indicated that proteolytic processing of raptor
participated in the cell death sensitivity, which is essential for
impairing mTORC1 functions and promoting cell death
signaling.
Recent structural evidences support a model in which the
mTORC1 forms a dimeric circle-like structure, composed of
two raptor molecules and two mTOR molecules.8,9 The close
interactions between raptor and the mTOR kinase are
essential for the stability of the mTORC1, but also for the
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recruitment of mTOR substrates towards the mTOR kinase
domain by the action of raptor.
Raptor being the cement of the mTORC1, the identification
of its cleavage by caspases reveals an important new
aspect of mTORC1 regulation. Several reports have high-
lighted the dissociation of raptor from mTOR after incubation
with rapamycin10 or curcumin,11 two drugs affecting the
proliferation of cancer cells. Our findings suggest that the
apoptotic cascade, triggered by different drugs, efficiently
inhibits mTORC1 by cleaving raptor, which perturbates the
recruitment of mTOR substrates by raptor. Moreover, similarly
to the translation initiation factor, 4E-BP1, which can be
cleaved by caspases during apoptosis,12 the generated
cleaved fragment of raptor could act as a proapoptotic
fragment, competing with the remaining uncleaved and
mTOR-bound raptor for the mTOR substrates and thus
inhibiting mTORC1 signalosome. Collectively, these findings
reveal an essential role of caspases in repressing mTORC1
functions during apoptosis, which irreversibly leads to
cell death.
Our findings not only highlight a mechanism of mTOR
regulation but also identify a new target for caspase-6 during
apoptosis. Since this atypical caspase has been implicated in
neurological diseases, such as Alzheimer’s, Parkinson’s and
Huntington’s diseases, caspase-6-mediated mTORC1 regula-
tion may be relevant in these age-related diseases.13 Active
caspase-6 has been correlated with Alzheimer’s disease
progression, due to its role in the cleavage of cytoskeletal
proteins like α-tubulin, α-actinin-4 and spinophilin, which
impairs the cytoskeleton network of neurons. Furthermore,
caspase-6 can also cleave Tau, huntingtin and the amyloid
precursor protein, also leading to axonal degeneration.14,15
The discovery of the caspase-6-mediated proteolytic proces-
sing of raptor highlights another level of regulation of the
mTORC1, which could be important for neurotoxicity and
neurodegeneration.
In conclusion, we propose a new caspase-6- and raptor-
dependent mechanism of mTORC1 inhibition, which could be
exploited to develop new chemotherapeutic strategies. In this
context, a synergistic effect could be obtained by combining
mTOR kinase inhibitors with anti-cancer drug-activating
caspases, giving rise to a strong repression of the mTORC1
and thus offering new therapeutic perspectives for a large
range of human diseases.
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Figure 1 Mechanisms of the caspase-6-driven inhibition of mTORC1. The left panel shows the stabilizing interaction between raptor and mTOR and its crucial role in
regulating mTOR kinase activity towards S6K and 4E-BP1, both of which participate in the regulation of protein translation during cell growth. The right panel represents molecular
mechanisms triggered by chemotherapeutic drugs. Rapamycin, curcumin, etoposide, cisplatin, staurosporine and FasL induce activation of caspase-6, among other caspases,
which cleaves the mTORC1-specific protein, raptor, at two precise residues, thus weakening its interaction with mTOR. The caspase-6-mediated proteolysis of raptor perturbates
the mTOR kinase activity and participates in the apoptotic cascade. FAT, focal adhesion targeting; FATC, C-terminal focal adhesion targeting; FRB, FKBP12-rapamycin binding;
HEAT, huntingtin, elongation factor 3 (EF3), protein phosphatase 2A (PP2A), and the yeast kinase TOR1; RNC, raptor N-terminal conserved domain; WD, tryptophan-aspartic
acid (WD) dipeptide
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